# Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F and T121E02F in Healthy Postmenopausal Women

> **NCT01721993** · PHASE1 · COMPLETED · sponsor: **Thar Pharmaceuticals, Inc** · enrollment: 71 (actual)

## Conditions studied

- Healthy Postmenopausal Women

## Interventions

- **DRUG:** T121
- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT01721993
- **Lead sponsor:** Thar Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2014-07
- **Final completion:** 2014-08
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2015-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01721993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01721993, "Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F and T121E02F in Healthy Postmenopausal Women". Retrieved via MORVS 2026-10-31 from https://api.morvs.ai/clinical/NCT01721993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*